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Genomic Context Differs Between Human 
Dilated Cardiomyopathy and Hypertrophic 
Cardiomyopathy
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Matthew T. Wheeler , MD, PhD; Tess D. Pottinger, PhD; Avery C. Robinson, BS; Samuel D. Kearns, BS; 
Anthony M. Gacita, PhD; Zachary J. Schoppen , MD; Wenyu Pan, MD; Gene Kim, MD; Jane E. Wilcox, MD, MSc; 
Allen S. Anderson , MD; Euan A. Ashley , MD, PhD; Sharlene M. Day , MD; Thomas Cappola, MD, ScM; 
Gerald W. Dorn, II, MD; Elizabeth M. McNally , MD, PhD
BACKGROUND: Inherited cardiomyopathies display variable penetrance and expression, and a component of phenotypic vari-
ation is genetically determined. To evaluate the genetic contribution to this variable expression, we compared protein coding 
variation in the genomes of those with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
METHODS AND RESULTS: Nonsynonymous single- nucleotide variants (nsSNVs) were ascertained using whole genome sequenc-
ing from familial cases of HCM (n=56) or DCM (n=70) and correlated with echocardiographic information. Focusing on nsS-
NVs in 102 genes linked to inherited cardiomyopathies, we correlated the number of nsSNVs per person with left ventricular 
measurements. Principal component analysis and generalized linear models were applied to identify the probability of cardio-
myopathy type as it related to the number of nsSNVs in cardiomyopathy genes. The probability of having DCM significantly 
increased as the number of cardiomyopathy gene nsSNVs per person increased. The increase in nsSNVs in cardiomyopathy 
genes significantly associated with reduced left ventricular ejection fraction and increased left ventricular diameter for individu-
als carrying a DCM diagnosis, but not for those with HCM. Resampling was used to identify genes with aberrant cumulative 
allele frequencies, identifying potential modifier genes for cardiomyopathy.
CONCLUSIONS: Participants with DCM had more nsSNVs per person in cardiomyopathy genes than participants with HCM. The 
nsSNV burden in cardiomyopathy genes did not correlate with the probability or manifestation of left ventricular measures in 
HCM. These findings support the concept that increased variation in cardiomyopathy genes creates a genetic background 
that predisposes to DCM and increased disease severity.
Key Words: dilated cardiomyopathy ■ hypertrophic cardiomyopathy ■ modifier genes ■ variable expressivity ■ variant burden
Heart failure affects >5 million Americans and is of growing health and economic concern.1 A leading cause of heart failure is cardiomyop-
athy, a disease with a strong heritable component. 
The 2 most common forms of cardiomyopathy are 
hypertrophic cardiomyopathy (HCM) and dilated 
cardiomyopathy (DCM). HCM occurs in 1:200 - 500 
adults and is characterized by gross hypertrophy of 
the septum and left ventricular (LV) free wall.2,3 DCM 
is found in ≈1:250 - 500 adults and presents with re-
duced LV ejection fraction (LVEF) and dilation.4,5 Over 
100 genes are implicated in the pathogenesis of car-
diomyopathy, and most cardiomyopathy is inherited 
in an autosomal dominant manner. Two genes, MYH7 
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and MYBPC3, are responsible for >80% of genetic 
HCM, making HCM largely a disease of sarcomere 
dysfunction.2,6– 8 DCM is more genetically heteroge-
neous, with mutations in one gene, TTN, accounting 
for ≈15% to 20% of inherited DCM; the other mu-
tations are found in genes encoding cytoskeletal, 
nucleoskeletal, mitochondrial, myofilament, and cal-
cium handling proteins.5,9,10 A feature of both HCM 
and DCM is variable expressivity and penetrance.11 
Genetic heterogeneity and variable expressivity imply 
a more complex inheritance, and some studies sup-
port oligogenic contributions to pathogenesis.12– 14
Genetic testing for cardiomyopathies has emerged 
as a useful clinical tool for both disease diagnosis and 
risk stratification.15,16 Rare variants account for most 
primary mutations in inherited cardiomyopathy, with 
few hot spots or recurrent mutations. Variant interpre-
tation considers population frequency, in silico tools 
of pathogenicity, and previous reports of clinical and 
functional outcomes. Current cardiac genetic testing 
samples 20 to 100 genes, and depending on the pri-
mary indication, gene panel testing has ≈50% sensi-
tivity. This reduced sensitivity or “missing heritability” 
for cardiomyopathy may be attributable to multiple 
factors, including (1) undiscovered primary or “driver” 
gene mutations and/or (2) an oligogenic or modifier ge-
netic mechanism involving the interplay between highly 
penetrant variants and the genomic context in which 
they are expressed.
Whole genome sequencing (WGS) is an effective 
means to determine both rare and common variation. 
Herein, we applied WGS to 126 subjects with either 
familial HCM or DCM from whom echocardiographic 
measurements were available. We examined varia-
tion in 102 cardiomyopathy genes routinely assayed 
in clinical gene testing panels. Both linear and logistic 
regression models revealed that subjects with more 
nonsynonymous coding variants per person in the 102 
cardiomyopathy genes were significantly more likely 
to express a DCM clinical phenotype as opposed to 
an HCM phenotype. These data also held true for 
high- frequency gene variants in the cardiomyopathy 
cohort. The number of cardiomyopathy gene variants 
per person also associated with reduced ejection 
fraction and increased LV diameter in subjects with 
DCM, but not subjects with HCM. These results sug-
gest that distinct genetic landscapes exist between 
HCM and DCM and that greater genetic variation in 
cardiomyopathy genes may be partially responsible 
for the unfavorable ventricular remodeling with re-
duced systolic function in DCM compared with HCM.
METHODS
Detailed methods available in Data S1. The study 
was approved by the Institutional Review Boards at 
University of Chicago, Stanford University, University 
of Michigan, and Northwestern University. All subjects 
provided written informed consent.
Because of the sensitive nature of the data collected 
for this study, requests to access the data set from 
qualified researchers trained in human subject confi-




• Dilated and hypertrophic cardiomyopathy are 
highly variable in onset and progression of dis-
ease severity, indicating that modifiers, includ-
ing genetic modifiers, play a role in disease 
expression.
• We evaluated and compared genome- wide 
coding variation in dilated cardiomyopathy and 
hypertrophic cardiomyopathy cases to query 
whether genomic backgrounds differ.
What Are the Clinical Implications?
• We evaluated missense single- nucleotide vari-
ation in genes associated with cardiomyopathy 
and found that the number of genetic changes 
per person increased the probability to having 
dilated cardiomyopathy but not hypertrophic 
cardiomyopathy and correlated with more se-
vere disease.
• The distinct genetic landscapes between hy-
pertrophic cardiomyopathy and dilated cardio-
myopathy suggest that greater genetic variation 
in cardiomyopathy genes provokes unfavorable 
disease expression in dilated cardiomyopathy.
Nonstandard Abbreviations and Acronyms
DCM dilated cardiomyopathy
gnomAD Genome Aggregation Database
HCM hypertrophic cardiomyopathy
IVSd interventricular septal end diastole
LVIDd left ventricle internal diameter end 
diastole
LVPWd left ventricular posterior wall end 
diastole
nsSNV nonsynonymous single- nucleotide 
variant
PC principal component
PCA principal component analysis
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Study Subjects
Subjects with nonischemic DCM or HCM with familial 
disease were selected for WGS.
Generation of WGS Data
Genomic DNA was determined using the Illumina 
HiSeq2000, 2500, or XTen and mapped to National 
Center for Biotechnology Information hg19 with 
MegaSeq.17 Only genomes with coverage >30× 
were included. Variant effects were predicted using 
snpEff.18
Ancestry Principal Component Analysis
Principal component analysis (PCA) was used to esti-
mate global ancestry through dimensional reduction. 
PCAs were conducted using singular- value decompo-
sition of shared variants using ≈5 million biallelic vari-
ants selected from across the genome using PLINK 
v1.9 and R 3.2.3.
Echocardiography PCA
PCA was performed using the R function prcomp (R 
statistical software version 3.4.1) on scaled and cen-
tered LVEF, LV internal diameter end diastole (LVIDd), 
interventricular septal end diastole (IVSd), and LV pos-
terior wall end diastole (LVPWd). All dimensions were 
adjusted to body surface area (BSA).
Linear Models
Multivariate and univariate linear models were fit 
using the lm function of R (R statistical software ver-
sion 3.4.1). Model significance was assessed using a 
χ2 test on reduction in the residual sum of squares. 
The response variables were echocardiographic 
measures or their principal components, and the 
independent variables were nonsynonymous single- 
nucleotide variants (nsSNVs), genetic ancestry, and 
platform.
Generalized Linear Model
Multivariate and univariate logistic regressions were 
fit using the generalized linear model R function, glm, 
with binomial link function. The response variable was 
whether a patient had DCM as opposed to HCM. 
The number of nsSNVs per patient was used as an 
independent variable in the primary analysis. Variant 
frequency subsets, defined by Genome Aggregation 
Database (gnomAD) exome allele frequency in both the 
cardiomyopathy genes and across all high- expression 
heart genes, were used for secondary analysis. P val-
ues correspond to the R analysis of deviance test func-
tion and therefore refer to comparison between nested 
models.
Resampling- Based Estimation of Excess 
Nonsynonymous Variation
A bootstrap approach was designed where each ran-
dom sample with replacement was taken from the 
126- subject set without constraining for cardiomyo-
pathy subtype, sex, or ancestry to mimic the original 
sample collection method. We calculated excess allele 
counts, subtracting baseline values computed assum-
ing ancestral gnomAD exome frequencies for African 
ancestry and non- Finnish European ancestry as refer-
ence values, including the sex chromosome number 
in each subject in the sample. Once corrected, allele 
numbers were summed over each of the cardiomyo-
pathy genes, then in high- expression heart genes, cre-
ating observed excess cumulative allele numbers. The 
empirical CIs for these cumulative allele frequencies 
were estimated using 5000 bootstrap samples. The 
bootstrap samples were created by sampling with re-
placement using subjects as the sampling unit. These 
calculations were performed using in- house functions 
in R. Significance was assessed using a false discov-
ery rate <0.25.
RESULTS
Cardiomyopathy Subject Selection and 
WGS
Subjects with nonischemic DCM (n=70) or HCM (n=56) 
with familial disease were selected for WGS analysis 
(Table  1). Detailed family history of cardiomyopathy 
was available for all subjects. Subjects were retrospec-
tively recruited from specialized clinics at the University 
of Chicago, Stanford University, University of Michigan, 
and Northwestern University. Genetic ancestry was 
determined using PCA of ≈5 million biallelic markers, 
and individuals were classified as African and non- 
African based largely on principal component (PC) 1. 
Genetic analysis revealed that one pair of individuals 
was distantly related (half uncle relation), and subjects 
were otherwise unrelated. At the outset, 35 individu-
als with MYH7 mutations were selected for the HCM 
cohort. These MYH7- mutation carriers served as an 
internal control when identifying genes/pathways en-
riched for genetic burden.
To focus on missense protein coding variation, 
only nsSNVs were studied. After excluding insertion/
deletions, missense variants accounted for 96% of 
total variants, and nonsense variants constituted the 
remaining 4%. More than one platform was used 
for WGS, and the number of single- nucleotide vari-
ants identified across platforms did not differ (t test; 
P=0.32; R2=0.008). A cardiomyopathy gene list (102 
genes) was generated from commercial testing pan-
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sequenced cohort (Table S1). When evaluating these 
102 genes, 10 357 nsSNVs were identified across the 
126 genomes, and missense variation accounted for 
97.4% of all variants. Table S2 provides the distribution 
of nsSNVs per person in 102 cardiomyopathy genes 
for DCM and HCM. Pathogenic, likely pathogenic, 
and suspicious variants of uncertain significance were 
identified in each subject and curated using evidence 
from ClinVar and expert input (Table S3).
PCA of Echocardiographic Measures
Echocardiographic LV measurements were used to 
correlate genetic data with phenotype. Cardiac dimen-
sions were normalized to BSA. LVEF, LVIDd, IVSd, and 
LVPWd were significantly different between the DCM 
and HCM cohorts, consistent with the primary diag-
nosis (Figure S1 and Table 2). PCA was performed on 
measures of LVEF, LVIDd/BSA, IVSd/BSA, and LVPWd/
BSA. Figure S2A shows that the first PC of echocar-
diographic measures (PC1) accounted for 59% of the 
variance, whereas PC2 accounted for 25%, PC3 ac-
counted for 11%, and PC4 accounted for 5% (Table S4 
and Figure S2A). Figure 1A illustrates that echocardio-
graphic PC1 reliably separated cardiomyopathy sub-
types, in addition to explaining most of the variance. 
Component loadings of each phenotype demonstrated 
the contribution of LV functional measures to the first 
2 components (Figure S2B). Collectively, this suggests 
that echocardiographic PC1 is a simple quantitative 
variable for illustrating the echocardiographic differ-
ences between DCM and HCM.
To determine if the variability of echocardiographic 
PC1 could be partially explained by cumulative 
genetic factors, we queried the number of nsSNVs 
per person in the 102 cardiomyopathy genes. 
Regression of echocardiographic PC1 against the 
number of nsSNVs per person in cardiomyopathy 
genes was significant (n=126; P=0.0019), indicating 
that the number of nsSNVs per person contributes 
to the echocardiographic differences between 
DCM and HCM (Figure  1B). This model using total 
cardiomyopathy gene nsSNVs per person (n=10 357 
total variants), as a linear predictor, accounted for 
11.5% of the variance of echocardiographic PC1. To 
determine the contribution of pathogenic variants/
likely pathogenic variants/suspicious variants of 
uncertain significance, the analysis was performed 
adjusting for pathogenic variants/likely pathogenic 
variants/suspicious variants of uncertain significance 
(Table S3; n=71), and this did not affect significance 
or size of effect. In addition, a supporting subgroup 







Age at echocardiogram, mean±SD, y (N) 41±16 (61) 47±14 (48) 0.06*
Ejection fraction, %, median (IQR) (N) 21 (15– 35) (61) 65 (60– 70) (48) <0.0001
Left ventricle internal diameter, diastole/BSA, median (IQR), cm/m2 (N) 3.1 (2.9– 3.7) (43) 2.3 (2.0– 2.6) (45) <0.0001
Interventricular septum, diastole/BSA, median (IQR), cm/m2 (N) 0.5 (0.47– 0.60) (39) 0.85 (0.70– 1.1) (46) <0.0001
Left ventricle posterior wall thickness, diastole/BSA, median (IQR), cm/m2 (N) 0.51 (0.44– 0.59) (39) 0.61 (0.52– 0.72) (45) 0.002
Measurements were normalized to BSA (m2), where indicated. The t test was performed, unless otherwise noted. BSA indicates body surface area; IQR, 
interquartile range (first and third quartiles); and LV, left ventricular.
*Nonparametric unpaired Mann- Whitney test was performed.
Table 1. Demographic Characteristics of Cohort Subjects
Demographics Dilated Cardiomyopathy Hypertrophic Cardiomyopathy P Value
No. 70 56
Male sex, n (%) 42 (60) 32 (57) 0.48
Age, mean±SD, y* 39±16 45±15 0.08†
Genetic race, n (%)
African ancestry 18 (25)‡ 6 (11) 0.04
Non- African ancestry 53 (75) 50 (89) 0.04
Ascertained for MYH7‡ 0 (0) 35 (62) <0.0001
The χ2 test was performed, unless otherwise noted.
*Age at presentation.
†Nonparametric unpaired Mann- Whitney test was performed. Individuals classified as Hispanic and other were reclassified as non- African ancestry on the 
basis of genetically determined best- fit ancestry.
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analysis was performed to determine if the trend 
remained consistent within ethnically homogeneous 
groups. When subjects with either Hispanic or African 
ancestry were removed, the estimates remained 
significant (P=0.005 and n=73 and P=0.024 and 
n=70, respectively; Table S5). When the sample was 
restricted to only European ancestry subjects, reducing 
the number of subjects by a third, the general trend 
remained unaffected, with a borderline significant P 
value (P=0.069). Together, these data indicate that 
the variance in echocardiographic PC1 is, in part, 
explained by the number of cardiomyopathy gene 
nsSNVs per person. As a control, we also considered 
sequencing platform in addition to echocardiographic 
PC1 and nsSNVs, and this resulted in no change 
in the coefficient (0.039, for both models) slope or 
significance (P=0.002) (Figure  S3). Together, these 
data indicate that greater protein coding variation 
in cardiomyopathy genes accounts, in part, for the 
differences in LV measures between DCM and HCM.
Probability of DCM Relative to 
HCM Increases With the Number of 
Cardiomyopathy Gene nsSNVs
To illustrate the association between these cardiomy-
opathy subtypes and the number of cardiomyopathy 
gene nsSNVs per person, a simple generalized mul-
tivariate linear model was fitted using a standard 
stepwise procedure based on analysis of deviance 
and Akaike Information Criterion. Because DCM and 
HCM genome sequencing was imbalanced across 
sequencing platform, it was included as an adjust-
ment to the model (Table  S6). Adding the number 
of cardiomyopathy gene nsSNVs per person to the 
model significantly improved the fit and the ability to 
predict DCM in this cohort (Table S6; P=0.021), and 
this analysis demonstrates a cumulative genetic fac-
tor model where having more nsSNVs predisposes 
to DCM (Figure  2). Adding genetic ancestry to this 
model neither improved the fit nor negated the con-
tribution of the number of nsSNVs, thus showing a 
robust dependency between cardiomyopathy sub-
type and number of nsSNVs (Table S6).
We assessed the contribution of moderate pop-
ulation frequency nsSNVs, defined by gnomAD 
exome global frequency (Figure  2, right panel). We 
found that the per- person number of cardiomyop-
athy gene nsSNVs in the 25% to 50% population 
frequency spectrum predicted DCM versus HCM 
using a nested model with platform and number of 
nsSNVs, similar to the above analysis (analysis of 
deviance=0.023; Table S6). Although adding ances-
try to the model improved fit, it did not change the 
Figure 1. Principal component analysis (PCA) of echocardiographic data separates hypertrophic 
cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) and is predicted by the number of 
nonsynonymous single- nucleotide variants (nsSNVs) in cardiomyopathy genes.
A, PCA of echocardiography data shows that echocardiographic principal component 1 (Echo PC1) 
summarizes the difference in echocardiography data between HCM (red) and DCM (black). B, Regression 
of Echo PC1 against the number of cardiomyopathy gene nsSNVs/person was significant and effectively 
separated HCM and DCM, as seen by the solid gray line (n=82). To account for genetic ancestry, linear 
regression was repeated in the absence of African ancestry (n=70) subjects (dashed gray line) or Hispanic 
ancestry (n=73) subjects (dot- dash gray line) or using only the European ancestry (dotted gray line; n=58) 
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coefficient (0.110 for number of nsSNVs). Using ns-
SNVs from genes with low expression in the heart 
showed no ability to predict the probability of DCM 
and HCM (Table  S6). We also completed an anal-
ysis using additional frequency bins and found no 
qualitative difference in the direction of the effect 
(Table S7 and Figure S4). Although underpowered to 
evaluate all frequency subsets, these data suggest 
that the number of nsSNVs per person predicts DCM 
compared with HCM across the frequency spec-
trum. Together, these data indicate that the number 
of cardiomyopathy gene nsSNVs associates with the 
DCM cardiomyopathy subtype.
Number of Cardiomyopathy Gene nsSNVs 
Associates With Disease Severity in DCM
To interrogate the relationship between the number of 
cardiomyopathy gene nsSNVs and disease severity, 
we regressed individual LV measures against the num-
ber of nsSNVs per person in cardiomyopathy genes 
(Figure 3A and 3B). Reduced LVEF and increased 
LVIDd were each significantly dependent on the num-
ber of cardiomyopathy gene nsSNVs per subject with 
DCM (Table  S8). In subjects with HCM, the number 
of cardiomyopathy gene nsSNVs was not significantly 
associated with either LVEF or LVIDd (Table S8). IVSd 
and LVPWd, both hallmarks of HCM, also showed no 
association with cardiomyopathy gene nsSNV number 
(Table S8).
To determine if these results were specific for 
cardiomyopathy gene nsSNVs and not the result of 
overall genomic burden, we separated all genes into 
either high or low cardiac expression groups using 
gene expression levels derived from genotype- tissue 
expression (see Data S1 and Figure  S5). We used 
low expression heart genes to determine if the asso-
ciation between LV measures and cardiomyopathy 
gene number nsSNV was specific, reasoning that 
low expression heart genes should play a lesser role 
in LV function. We considered variation per person in 
89 randomly selected genes from the low- expression 
heart genes to match the 89 cardiomyopathy genes 
that carry variation in the HCM/DCM cohort, and re-
peated this process 1000 times. Using both total and 
25% to 50% allele frequency, nsSNVs from these ran-
domly selected low- expression heart genes revealed 
minor qualitative trends; however, no statistical as-
sociation between LVEF, LVIDd, IVSd, or LVPWd with 
nsSNV count was observed (Figure 3C and 3D and 
Table S9). We cannot exclude that a type II error is 
not driving these results; however, total nsSNVs en-
compass cardiomyopathy nsSNVs and therefore will 
provide a weaker, but nonzero, predictor.
Figure 2. Dilated cardiomyopathy (DCM) probability is increased with cardiomyopathy gene nonsynonymous single- 
nucleotide variant (nsSNV) number compared with hypertrophic cardiomyopathy (HCM).
Multivariate generalized linear models demonstrate that the probability of DCM is increased with the total number of cardiomyopathy 
gene nsSNVs per person in this cohort (left panel). The red and black dots represent individual participants and their number of 
nsSNVs in cardiomyopathy genes. The analysis on the left considered all nsSNVs in cardiomyopathy genes, including rare and high- 
frequency variants. The right- hand panel shows the same analysis when considering only high- frequency cardiomyopathy gene 
nsSNVs, where the same trend was evident (allele frequency, 0.25– 0.50 variants included). DCM is black, and HCM is red. P values 
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Together, these results indicate that the probability 
and severity for each subject with DCM, relative to sub-
jects with HCM, are associated with increasing non-
synonymous variant load in cardiomyopathy genes.
Genes With Deviant Cumulative Variant 
Frequency in DCM and HCM
To identify candidate genes that contribute to the dif-
ferences in variant load between DCM and HCM, we 
investigated if any genes had aberrant cumulative 
variant frequencies compared with gnomAD exome 
frequency data. Ancestral allele frequencies were 
compared with the allele frequencies in each bootstrap 
sample, generating excess cumulative allele frequen-
cies for each gene, and this process was repeated 
5000 times. The resulting values for DCM and HCM 
were subtracted from each other to produce Delta 
(schematic shown in Figure S6).
Three cardiomyopathy genes had excess cumu-
lative frequencies that were statistically significant at 
false discovery rate <0.25 (Figure 4).19 We originally se-
lected 35 of 56 subjects with HCM based on MYH7 
variant carrier status, so, if reliable, the bootstrap 
method should identify MYH7 variation as enriched 
in the HCM cohort and serve as an internal control. 
MYH7 was significantly enriched for variation in the 
HCM cohort. LMNA was significantly enriched in DCM, 
Figure 3. The number of cardiomyopathy gene nonsynonymous single- nucleotide variants 
(nsSNVs) per person associates with reduced cardiac function and increased left ventricular (LV) 
diameter.
LV ejection fraction (LVEF) (A) and left ventricular internal diameter end diastole (LVIDd), normalized to 
body surface area (BSA) (B), were regressed against the total number of cardiomyopathy gene nsSNVs per 
person. Cardiomyopathy gene nsSNV number significantly correlated with reduced LVEF and increased 
LVIDd in subjects with dilated cardiomyopathy (DCM), and this correlation was not seen for subjects with 
hypertrophic cardiomyopathy (HCM) (*LVEF DCM P=0.01; HCM P=0.78; **LVIDd/BSA DCM P=0.02; HCM 
P=0.34); gray shading represents 95% CIs (see Table S6 for values). A randomly selected group of genes 
with comparable variant numbers was chosen from the low- expression heart genes and similarly tested. 
This process was repeated 1000 times with different groups of genes. LVEF (C) and LVIDd/BSA (D) were 
regressed against low- expression heart genes, and the regression lines did not reveal any significant 




 http://ahajournals.org by on M
ay 4, 2021
J Am Heart Assoc. 2021;10:e019944. DOI: 10.1161/JAHA.120.019944 8
Puckelwartz et al Genetic Landscape of DCM and HCM
fitting well with LMNA’s known role in the pathogenesis 
of DCM.20 Together, these data support this method 
of calculating deviant allele frequencies while adjusting 
for ancestry and sex.
We repeated the bootstrap analysis on genes with 
high heart expression (as defined in Figure S5). In this 
exploratory analysis of 7306 cardiac genes, 8 had 
excess cumulative frequencies that differed between 
HCM and DCM with a false discovery rate <0.25 
(Figure 4B). Table S10 provides, in ranked order, the 
genotype- tissue expression levels in heart for these 
genes and any previous genome- wide association 
study from the genome- wide association study cata-
log (https://www.ebi.ac.uk/gwas). Two of these genes, 
ANKRD9, encoding ankyrin repeat domain 9, and 
CD36, encoding the thrombospondin receptor, have 
previously been associated with cardiac phenotypes 
of QT interval and LV mass, respectively.21,22
DISCUSSION
Cardiomyopathy Gene Variation Differs 
Between DCM and HCM
Cascade family testing for primary gene mutations 
highlights the range of clinical expression seen with 
genetic variants.23 Environmental factors and other ge-
netic variants contribute to this variable expressivity. In 
this report, we identified that the number of nsSNVs 
in cardiomyopathy genes correlated with DCM but 
not HCM. Notably, we found the number of nonsyn-
onymous variants in cardiomyopathy genes correlated 
not only for DCM diagnosis compared with HCM, but 
also for specific aspects of DCM, including reduced LV 
function and increased LV size. These findings were 
evident in cardiomyopathy genes and were not present 
in low- expression heart genes.
Identifying common variation that contributes to 
cardiomyopathy disease expression would aid in the 
development of genomic risk scores for cardiomyopa-
thy. A large- scale genome- wide association study and 
multitrait analysis in HCM, DCM, and LV traits from UK 
Biobank participants with healthy hearts revealed loci 
associated with each cardiomyopathy subtype and with 
LV measures.24 The study identified strong genetic cor-
relations with the cardiomyopathies and LV traits. We 
also identified correlations with cardiac dimensions and 
cardiomyopathy subtype. The authors further gener-
ated polygenic risk scores and found that for subjects 
with HCM carrying a rare, disease- causing variant, 
common variation accounted for phenotypic variability 
in subjects with HCM. Our data are consistent with this 
concept (namely, that common variation is contributing 
to disease variability in the cardiomyopathies).
Oligogenic Inheritance in Cardiomyopathies 
and Implications for Genetic Testing
In light of the reduced penetrance and expressivity of 
familial cardiomyopathies, modifying factors of disease 
Figure 4. Resampling identifies genes with deviant cumulative missense allele frequencies that 
may modify dilated cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM).
The bootstrap method (5000 resampling with replacement tests) was used to identify excess nonsynonymous 
single- nucleotide variant burden in DCM compared with HCM (Delta) in either cardiomyopathy genes (A) 
or high- expression heart genes (B). When conducting this analysis on cardiomyopathy genes, MYH7 and 
BAG3 were identified as having increased cumulative variation in HCM. MYH7 was expected to appear 
in this analysis because MYH7 mutations were enriched in the HCM cohort, and thus serve as an internal 
control for this approach. From known cardiomyopathy genes, BAG3 was identified as being enriched in 
HCM over DCM, and LMNA variation was enriched in DCM over HCM. This bootstrap method was applied 
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have been postulated.11 We now identified potential 
modifiers of cardiomyopathy using a random resam-
pling method. We identified expected genes, including 
MYH7 in HCM and LMNA in DCM. The identification 
of additional variants that may act in concert to cause 
disease or affect severity suggests oligogenic inher-
itance. Functional experiments using CRISPR- Cas9 
now allow testing of multiple variants in concert. Recent 
work by Gifford and colleagues identified a family with 
asymptomatic parents and 3 children with early- onset 
heart disease.25 Exome sequencing revealed a com-
plex inheritance, with 3 variants likely contributing to 
disease. In vivo gene editing techniques revealed that 
variants in MKL2, MYH7, and NKX2- 5 act together 
to cause LV noncompaction. The 2 variants in MKL2 
and MYH7 were paternally inherited and unique to the 
family, whereas the maternal NKX2- 5 allele was rare. 
Experimental modeling confirmed the role of these 
variants in disease and established NKX2- 5 as a modi-
fier of disease. These data support our hypothesis that 
modifying variants may make a significant contribution 
to disease phenotype.
Despite progress, likely pathogenic or pathogenic 
variants are found in less than half of cases, depend-
ing on the type of cardiomyopathy.26 Recent work by 
Haas et al used deep sequencing of 76 cardiomyop-
athy genes in a large cohort of 639 people with DCM 
and found that >38% patients had compound or com-
bined rare mutations, further supporting oligogenic 
contribution.20 Cowan and colleagues reexamined 
19 pedigrees with LMNA- associated cardiomyopathy 
with cardiomyopathy- positive family members who did 
not have the “causal” LMNA gene variant, suggest-
ing additional genetic causes of disease.27 In a large 
DCM cohort with 1040 subjects, Mazzarotto et al se-
quenced 56 cardiomyopathy genes and found robust 
disease association with 12 of those genes, explaining 
17% of cases and 26% of cases in a validation cohort 
with 1498 subjects.28 Our data indicate that variant 
load plays an important role in both the manifestation 
and severity of DCM. The clinical utility of knowing vari-
ant load and how this relates to an individual’s disease 
progression is not established and requires additional 
study. However, the concept of oligogenic inheritance 
in DCM provides one path to better understanding 
variable expressivity. Highly penetrant, rare variants 
provide risk knowledge, and additional variants may 
ultimately help refine that risk.
In this study, we examined the genetic landscape that 
differentiates DCM and HCM using a cohort in which 
individual- level data, both clinical and genetic, were 
available. To define genetic drivers of cardiomyopathy, 
a large well- phenotyped and genotyped control data 
set is required. Current data sets, such as gnomAD 
and others, provide a rich source of population- level 
allele frequency information. However, these data sets, 
by design, cannot be used to parse the contributions of 
allele combinations on disease state because they pro-
vide aggregate data. Moving the forefront of precision 
medicine requires deep sequencing and phenotype in-
formation while protecting subjects’ privacy.
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EXPANDED MATERIALS & METHODS 
 
Study subjects.  Non-ischemic dilated or hypertrophic cardiomyopathy subjects with familial 
disease were selected for whole genome sequencing (WGS).  Detailed family history of 
cardiomyopathy was available for all subjects.  Subjects were retrospectively recruited from 
specialized clinics at the University of Chicago, Stanford University, University of Michigan and 
Northwestern University.  Subjects were selected based on a diagnosis of familial non-ischemic 
dilated cardiomyopathy or familial hypertrophic cardiomyopathy.  Preference was given to 
subjects who had previous genetic testing and for whom a primary mutation was not identified, 
except in the case of selected MYH7 variants and for whom echocardiographic data was 
available.  Echocardiographic measurements were excluded if age at test was ≤ 17 years old or 
if the subject had a myectomy.   
 
Generation of whole genome sequence data.  Genomic DNA was extracted from peripheral 
blood.  Sequencing was performed using the Illumina HiSeq2000, 2500 or XTen to greater than 
30X coverage.  Paired-end reads were mapped to NCBI reference genome hg19.  Reads were 
aligned and variants were called using MegaSeq, a supercomputing pipeline using the open 
source Burrows Wheeler Aligner (BWA) and Genome Analysis Tool Kit (GATK).18  Variant 
effects were predicted using snpEff.19  Variant frequencies were annotated using frequencies 
from the gnomAD database (http://gnomad.broadinstitute.org/) accessed in March 2018.  Allele 
frequencies are reported as global, EA (non-Finnish European ancestry) or AA (African 
ancestry) for each variant.  When population allele frequency was used, only dataset variants 
with gnomAD exome coverage ≥ 8X were included in the analysis.  Indels and multi-allelic 
variants were removed from the working dataset.  Relatedness was accounted for using PLINK.   
 
Ancestry principal component analysis (PCA).  PCA was used to estimate global ancestry 
through dimensional reduction.  The 1st and 3rd component illustrated ancestry.  PCAs were 
conducted using singular-value decomposition of shared variants using ~5 million biallelic 
variants selected from across the genome using PLINK v1.9 and R 3.2.3.  
 
Cardiomyopathy gene selection.  Cardiomyopathy genes were identified based on their 
inclusion in one or more Cardiomyopathy gene testing panels of Partners Healthcare Laboratory 
for Molecular Medicine, GeneDx, and Invitae.   
 
Dichotomizing heart genes into high and low expression.  The Genotype-Tissue Expression 
(GTEx) database version 6p was downloaded Dec 2016 (https://www.gtexportal.org).  The 
GTEx dataset includes RNA sequence analysis of human left atrial appendage (referred to as 
AA in GTEX, n=264 samples, and referred to as LA in this report) and left ventricle (LV, n=272).  
Expression values in RPKM (Reads Per Kilobase Million) for left ventricle (LV) and atrial 
appendage (AA) were used for genes identified as having variation in the DCM and HCM WGS 
dataset (17,058 genes with a total of 1,744,423 variants).  Chromosome Y was removed that 
included 13 genes with 105 variants leaving 17,045 genes and 1,744,318 variants.  Genes 
without cardiac GTEx values were removed leaving 16,825 genes and 1,729,723 variants.  
Variants with gnomAD exome coverage less than 8X were excluded leaving 16,353 genes and 
1,635,325 variants.  Genes with known segmental duplications were also removed 
(genome.ucsc.edu; GenomicSuperDups Table, assessed March 2018), leaving 14,915 genes 
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values for AA as logarithms.  We overlaid the cardiomyopathy genes on this plot to create an 
expression space that encompasses genes expressed in the heart.   
 
Echocardiographic Data.  2-D echocardiographic measures were collated retrospectively from 
health records.  Left ventricular ejection fraction (EF), left ventricular internal diameter end 
diastole (LVIDd), interventricular septal end diastole (IVSd), and left ventricular posterior wall 
end diastole (LVPWd) and body surface area were collected when available.  If multiple 
echocardiograms were available, the study with the most abnormal measures was used. For 
DCM subjects, lowest EF was selected while for HCM subjects thickest IVSd was selected.  All 
measures were taken from only one study date.   
 
Echocardiography PCA.  Principal component analysis (PCA) was performed using the R 
function prcomp (R statistical software version 3.4.1) on scaled and centered left ventricular 
ejection fraction, left ventricular internal diameter end diastole (LVIDd), interventricular septal 
end diastole (IVSd), and left ventricular posterior wall end diastole (LVPWd).  All dimensions 
were adjusted to body surface area (BSA).  Variables were centered by subtracting the mean 
and scaled by dividing by the standard deviation to prevent measurement units from 
determining their importance.  
 
Linear models.  Multivariate and univariate linear models were fit using the lm function of R (R 
statistical software version 3.4.1).  Models were ranked in order of complexity (from one to four 
explanatory variables).  Models of the same complexity were compared using t-tests provided 
by R and estimated r-squared values, while nested models were compared using the R anova 
function to estimate whether additional variables improved the fit significantly.  Model 
significance was assessed using a chi-squared test on reduction in the residual sum of squares.  
Regression against random samples of genes were performed by randomly selecting 89 genes 
from the noncardiac gene list.  89 genes were selected to match the number of genes in the 
cardiomyopathy genes with nsSNVs.  The sample was checked to ensure that the minimum and 
maximum number of variants in the randomly selected set were within 1 standard deviation from 
the minimum and the maximum number of variants of the 89 cardiomyopathy genes.  This was 
repeated until 1000 sets met criteria.  Linear regression of phenotype against these gene sets 
was performed as above.  Confidence intervals were estimated directly from the sample. 
 
Generalized linear model (GLM).  Multivariate and univariate generalized linear models (GLM) 
were fit using the R function, glm, with binomial link function, fit to a logistic model.  Models were 
generated using all nonsynonymous single nucleotide variants (nsSNVs) as primary analysis as 
well as variant frequency subsets defined by gnomAD exome allele frequency in both the 
cardiomyopathy genes and across all low-expression heart genes.  To control for the potentially 
confounding effects of sequencing platform and genetic ancestry, a standard step-wise 
approach was used selecting the best-fit model and adding additional variables (sequencing 
platform, race and number of nsSNVs) until either the Akaike information criterion (AIC) 
increased or Analysis of Deviance (R function anova) showed non-significant improvements.  
Additional variables were excluded if they did not qualitatively change the contribution of 
variants to the fit by comparing the estimated coefficient values.  P values correspond to the R 
anova (Analysis of Deviance test) function and therefore refer to the overall model.  
 
Resampling based estimation of excess nonsynonymous variation.  See Figure S5 for 
schematic.  Allele counts were aggregated by variant, sex, race, and cardiomyopathy type to 
create relatively homogeneous subsets.  Differences in variant frequencies due to race were 
compensated for using gnomAD exome allele frequencies for African (AFR) or European 
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male for chromosome X variants.  Based on the number of chromosomes in the race and 
cardiomyopathy subset of the cohort, the expected allele numbers using ancestral gnomAD 
frequencies were calculated and subtracted from the observed alleles in the subset to re-center 
allele number around the expected value.  These re-centered allele numbers were summed 
over each of the cardiomyopathy genes, then in high-expression heart genes set (as defined in 
Figure S5) creating observed excess cumulative allele numbers.  Allele numbers were divided 
by the total number of chromosomes in each bootstrap.  The empirical confidence intervals for 
these cumulative allele frequencies was estimated using 5,000 bootstrap samples.30  As proof of 
principle, we analyzed cardiomyopathy genes and identified genes with  significant differences 
between the subtypes.  The bootstrap samples were created by sampling with replacement 
using subjects as the sampling unit.  These calculations were performed using in-house 
functions in R.  Significance for the difference between the cardiomyopathy types was estimated 
using the empirical quantiles of the distribution of the bootstrap sample differences, 
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Table S1. Cardiomyopathy Genes. 
 
A2ML1 DOLK JUP NEXN SLC22A5 
ABCC9 DSC2 KRAS NF1 SOS1 
ACTC1 DSG2 LAMA4 NKX2-5 SOS2 
ACTN2 DSP LAMP2 NPPA SPRED1 
AGL DTNA LDB3 NRAS TAZ 
ALPK3 EMD LMNA PDLIM3 TCAP 
ANKRD1 EYA4 LRRC10 PKP2 TGFB3 
BAG3 FHL1 MAP2K1 PLEKHM2 TMEM43 
BRAF FHL2 MAP2K2 PLN TMPO 
CACNA1C FKRP MIB1 PRDM16 TNNC1 
CALR3 FKTN MURC PRKAG2 TNNI3 
CASQ2 FLNC MYBPC3 PTPN11 TNNT2 
CAV3 GAA MYH6 RAF1 TPM1 
CBL GATA4 MYH7 RASA1 TRDN 
CHRM2 GATA6 MYL2 RBM20 TTN 
CRYAB GATAD1 MYL3 RIT1 TTR 
CSRP3 GLA MYLK2 RRAS TXNRD2 
CTF1 HCN4 MYOM1 RYR2 VCL 
CTNNA3 HRAS MYOZ2 SCN5A  
DES ILK MYPN SGCD  
DMD JPH2 NEBL SHOC2  
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Table S2. Distribution of cardiomyopathy nsSNVs. 
 
Phenotype 1st quartile Median 3rd quartile 
DCM 71 85 95.8 
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Table S3. Pathogenic/Likely Pathogenic/Suspicious VUS in HCM and DCM subjects. 
 
Gene Variant Variant Designation Segregation 
ACTA1 p.W358S sVUS N/A 
BAG3 p.Q244* LP Yes 
DES c.735+3A>G P Yes 
DMD dup exons 3-9 P Yes 
DSP p.E1245_N1246fs LP Yes 
 p.Y1065* P Yes 
FLNC c.3791G>C sVUS N/A 
 p.C1013* P N/A 
 p.T291_V292fs P/LP N/A 
 p.S2457fs P N/A 
GLA p.R118C sVUS Yes 
LMNA p.R433H LP N/A 
MYBPC3 p.D1063_K1064fs LP Yes 
 c.1224T>G P N/A 
 p.W1097* P N/A 
 p.L156P sVUS N/A 
 p.P16S LP N/A 
 p.E541Q P Yes 
 p.R495Q P/LP Yes 
MYBPHL R255* LP Yes 
MYH6 p.A1004S P N/A 
MYH7 p.R1250W LP Yes 
 p.M982T sVUS Yes 
 p.L908V P Yes 
 p.A355T P N/A 
 p.H576R LP N/A 
 p.G1057S sVUS N/A 
 p.R663H P N/A 
 p.E1468K sVUS N/A 
 p.G716R P N/A 
 p.K847E LP N/A 
 p.A797T P N/A 
 p.G1057D sVUS N/A 
 p.R1606C sVUS N/A 
 p.R719W P N/A 
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MYH7 p.P731A sVUS N/A 
 p.N1327K sVUS N/A 
 p.I736T P N/A 
 p.V320M LP N/A 
 p.E497D P N/A 
 p.D906G P N/A 
 p.D469N sVUS N/A 
 p.R204H LP Yes 
 p.T1377M LP N/A 
 p.G741W P N/A 
 p.R1712Q LP N/A 
 p.E1455K sVUS N/A 
 p.R652G LP Yes 
 p.R403Q P N/A 
 p.R783H LP N/A 
RBM20 p.R634Q P Yes 
 p.R636H P Yes 
SCN5A p.R814W LP Yes 
 p.G1318V P/LP Yes 
 p.Arg1316* LP Yes 
TNNT2 K210del sVUS Yes 
 p.N274D sVUS N/A 
TPM1 p.D230N P Yes 
 p.E54K P/LP N/A 
 p.Leu254fs sVUS N/A 
TTN p.E3707* LP Yes 
 p.Phe20604_Leu20605fs P Yes 
 c.42521–5 C>G sVUS Yes 
 p.Tyr15330* sVUS N/A 
 p.R4386* sVUS N/A 
 c.17087G>A sVUS Yes 
 p.Val14761fs sVUS N/A 
 p.Leu18170fs sVUS N/A 
 p.Gly14825* sVUS N/A 
 p.R12136* LP N/A 
*P=pathogenic, LP=likely pathogenic, sVUS= suspicious variant of uncertain significance; as 
adjudicated using ClinVar, frequency data, subject phenotype and expert opinion.  Proband 
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Table S4. PCA Weights for Left Ventricular Measures. 
 
 PC1 PC2 PC3 PC4 
IVSd_BSA 0.52 -0.25 -0.81 -0.08 
LVPWd_BSA 0.29 -0.84 0.44 0.13 
LVIDd_BSA -.056 -0.39 -0.17 -0.71 
EF (%) 0.57 0.28 0.36 -0.68 
Proportion of 
Variance 0.59 0.25 0.11 0.05 
Cumulative 
Proportion 0.59 0.84 0.95 1.00 
PCA weights obtained by applying the R function prcomp to echocardiographic measures. 
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subjects Coefficient p value 
V(all)* 82 0.0391 0.0019 
No HA  73 0.0372 0.0055 
No AA  70 0.0314 0.0243 
Only EA 58 0.0272 0.0691 
*V(all) = total cardiomyopathy gene nsSNVs; Genetic ancestry 
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nsSNV p value* 
Analysis of 
Deviance AIC 
Total nsSNVs in cardiomyopathy genes 
Platform 1   4.15 x 10-5  160.2 
nsSNVs 1  0.026 0.053  174.41 
Ancestry 1 1.040  0.042  173.69 
Platform & 
nsSNVs 2  0.034 
0.025 
(nsSNVs) 0.021 156.85 
Platform & 
Ancestry 2 1.11  
0.043 
(Ancestry) 0.034 157.71 
Platform & 
nsSNVs & 
Ancestry 3 0.719 0.025  0.224 157.37 
nsSNVs in cardiomyopathy genes with gnomAD Frequency 0.25-0.50 
Platform 1   4.15 x 10-5  160.2 
nsSNVs 1  0.095 0.037  173.76 
Ancestry 1 1.040  0.042  173.69 
Platform & 
nsSNVs 2  0.110 
0.027 
(nsSNVs) 0.023 157.03 
Platform & 
Ancestry 2 1.11  
0.043 
(Ancestry) 0.034 157.71 
Platform & 
nsSNVs & 
Ancestry 3 1.11 0.110  0.037 154.67 
Total nsSNVs in low expression heart genes 
Platform 1 -1.59  4.15 x 10-5  160.2 
nsSNVs 1  0.0008 0.027  172.83 
Ancestry 1 1.04  0.042  173.69 
Platform & 
nsSNVs 2  0.0007 
0.055 
(nsSNVs) 0.045 158.17 
Platform & 
Ancestry 2 1.11  
0.043 
(Ancestry) 0.034 157.71 
Platform & 
nsSNVs & 
Ancestry 3 1.02 6.11 x 10-5  0.494 159.17 
nsSNVs in low expression heart genes with gnomAD Frequency 0.25-0.50 
Platform 1 -1.59  4.15 x 10-5  160.2 
nsSNVs 1  -0.002 0.28  177.09 
Ancestry 1 1.04  0.042  173.69 
Platform & 
nsSNVs 2  -0.003 
0.205 
(nsSNVs) 0.045 160.55 
Platform & 
Ancestry 2 1.11  
0.043 
(Ancestry) 0.034 157.71 
Platform & 
nsSNVs & 
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*p value cutoff of 0.1 used to determine variables for nested models.  Model with best fit is shaded 




 http://ahajournals.org by on M
ay 4, 2021






















 http://ahajournals.org by on M
ay 4, 2021
Table S8. Linear regression of phenotype against V(all)* 
 
Phenotype Coefficient P value 95% CI 
LVEF    
DCM -0.338 0.012 -0.593 - -0.082 
HCM -0.032 0.779 -0.258 – 0.193 
LVIDd/BSA    
DCM 0.017 0.024 0.003 – 0.031 
HCM 0.005 0.344 -0.005 – 0.016 
IVSd/BSA    
DCM 0.0001 0.934 -0.003 – 0.003 
HCM -0.0008 0.830 0.008 – 0.007 
LVPWd/BSA    
DCM 0.002 0.174 -0.235 – 0.239 
HCM 0.001 0.473 -0.002 – 0.004 
* V(all) = total nsSNVs in cardiomyopathy genes.  LVEF, Left ventricular ejection 
fraction; LVIDd/BSA, Left ventricular internal diameter at end diastole normalized 
to body surface area; IVSd/BSA, Interventricular septal end diastole normalized 
to BSA; LVPWd/BSA, Left ventricular posterior wall thickness at end diastole 
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Table S9. Confidence Intervals for Simulated Linear Regression. 
 
Phenotype 95% CI  
LVEF  
DCM -0.52 - 0.13 
HCM -0.33 - 0.32 
LVIDd/BSA  
DCM -0.01 - 0.03 
HCM -0.01 - 0.02 
IVSd/BSA  
DCM -0.003 - 0.003 
HCM -0.01 - 0.01 
LVPWd/BSA  
DCM -0.002 - 0.004 
HCM -0.004 - 0.005 
 
LVEF, Left ventricular ejection fraction; LVIDd/BSA, Left 
ventricular internal diameter at end diastole normalized to 
body surface area; IVSd/BSA, Interventricular septal end 
diastole normalized to BSA; LVPWd/BSA, Left ventricular 
posterior wall thickness at end diastole normalized to BSA. 
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Table S10. Cardiac expression levels and GWAS Associations of Cardiac Genes. 
 

















42.15 4 47.05 3 





85.38 6 147.5 4 
LV mass; RBC width; 
Mean corpuscular 
volume; RBC count; 
Platelet count; Mean 
















23.88 40 18.05 43 
Gut microbiota; 
Cerebral amyloid 
deposition in APOEe4 
non-carriers 
GSPT1 
G1 to S phase 
transition 
21.56 39 17.16 44 
Menopause (age of 


















*Rank relative expression in relation to 53 tissues included in GTEx dataset 
GWAS traits from the GWAS catalog (https://www.ebi.ac.uk/gwas). TPM= Transcripts Per 
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Figure S1. Left ventricle measurements of DCM and HCM subjects determined by 
echocardiography.   
 
 
(A) Left ventricular ejection fraction (LVEF), (B) Left ventricular internal diameter at end diastole 
normalized to body surface area (LVIDd/BSA), (C) Interventricular septal end diastole 
normalized to BSA (IVSd/BSA), and (D) Left ventricular posterior wall thickness at end diastole 
normalized to BSA (LVPWd/BSA) are shown for subjects with DCM (black) and HCM (red), 
(*p<0.05, t-test). DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy.  DCM 
participants had lower LVEF and larger LVIDd measurements, while HCM subjects had 
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PCA on echocardiographic measurements for the cardiomyopathy cohorts.  A) Scree plot 
showing the variance associated with each component.  B) Component loadings of each 
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Figure S3. Platform does not change the dependency between Echo PC1 and nsSNVs.   
 
 
PCA of echocardiography data revealed that PC1 summarizes the difference between HCM and 
DCM.  Regression of Echo PC1 against the number of cardiomyopathy gene nsSNVs per 
person demonstrates SNV number distinguishes cardiomyopathy subtype.  Platform was tested 
to determine if the either of the two platforms used in this study were responsible for the 
dependence of Echo PC1 on nsSNV number.  These data indicate that platform does not cause 
the dependency.  Squares represent subjects.  DCM, dilated cardiomyopathy (black); HCM, 
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Figure S4. The number of cardiomyopathy gene nsSNVs per person qualitatively predicts 




Multivariate generalized linear models suggest that the probability of DCM increases with the 
number of nsSNVs per person across frequency bins in this cohort.  The red and black dots 
represent individual participants and their number of nsSNVs in cardiomyopathy genes. (A) 0.1-
0.25; (B) <0.1 (C) <0.01 and (D) <0.0025. DCM (black), HCM (red). Number on X axis indicates 
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The expression of all genes (light blue circles) and genes linked to cardiomyopathies (dark blue 
triangles) was assessed in the Genotype-Tissue Expression (GTEx) database.  Genes linked to 
cardiomyopathy were those found in commercial and academic gene testing panels (n=102 
genes).  The logs of RPKM (Reads Per Kilobase Million) for the left atrium (left atrial 
appendage, n=264 samples) and left ventricle (n=272 samples) were plotted against each other 
for all genes with at least one variant in the HCM/DCM cohort (n=14915 genes in total).  Ninety-
eight genes of the 102 cardiomyopathy genes were contained in a well-defined subset of the 
expression space bounded from below by the expression values for FKTN (GTEx LA = 2.00) 
and CBL (GTEx LV = 1.49); denoted by the black dotted lines.  All genes with GTEx values 
below these cutoffs were considered low-expression heart genes (7,609 genes).  All genes with 
values equal to or greater than both of the above cutoffs constitute high-expression heart genes 
(7,306) genes.  Expression heat maps at each axis show increasing expression from red to 
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Schematic illustrating ancestral allele frequency correction performed on each nsSNV. nsSNV 
count was determined in cardiomyopathy and ancestry subgroups, and adjusted by gnomAD 
ancestral allele frequency.  Corrected allele frequencies were summed across each gene by 
cardiomyopathy subgroup and ancestry.  Delta is the difference in corrected allele frequency per 
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